PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered?

Authors :: Gray SG
Cuffe S
Finn SP
Source :: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2016 Nov; Vol. 11 (11), pp. e142-e144.
Publication Year :: 2016

Subjects :: Antineoplastic Agents therapeutic use
Carcinoma, Non-Small-Cell Lung drug therapy
Carcinoma, Non-Small-Cell Lung genetics
Carcinoma, Non-Small-Cell Lung immunology
Cell Cycle Checkpoints drug effects
Humans
Lung Neoplasms drug therapy
Lung Neoplasms genetics
Lung Neoplasms immunology
B7-H1 Antigen genetics
Biomarkers analysis
Carcinoma, Non-Small-Cell Lung diagnosis
Cell Cycle Checkpoints immunology
In Situ Hybridization methods
Lung Neoplasms diagnosis
RNA, Messenger genetics

Language :: English
ISSN :: 1556-1380
Volume :: 11
Issue :: 11
Database :: MEDLINE
Journal :: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Publication Type :: Editorial & Opinion
Accession number :: 27770977
Full Text :: https://doi.org/10.1016/j.jtho.2016.07.025

Full Text Access

Tools